Bris­tol-My­ers con­cedes a PhI­II lung can­cer flop for Op­di­vo as com­pe­ti­tion heats up in SCLC

Bris­tol-My­ers Squibb $BMY has run in­to an­oth­er dead end in ex­plor­ing the lung can­cer mar­ket. 

The big biotech re­port­ed that its Phase III study of Op­di­vo failed the Check­Mate-331 study, un­able to beat the stan­dard of care for treat­ing sec­ond-line small cell lung can­cer.

We don’t know yet just what the da­ta are, just that the read­out doesn’t mea­sure up to a win. And the set­back comes just months af­ter Roche’s com­bo us­ing Tecen­triq and chemo won out on first-line cas­es of SCLC, a tough field that ac­counts for about 15% of the over­all lung can­cer mar­ket.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN